Antihistamines in children and adolescents: A practical update
Main Article Content
Keywords
Histamine, H1 receptor, Antihistamines, Allergic disorders, Children, Adolescents
Abstract
Histamine is a chemical mediator, released predominantly by tissue mast cells, circulating basophils, and neurons, which are activated in response to various immunological and non-immunological stimuli. Histamine has to bind to specific receptors to exert its physiological and pathophysiological functions. Endogenous histamine is the main mediator of the immediate allergic response, which moreover, performs other multiple functions, including regulation of gastric secretion, neurotransmission in the central nervous system, and immunomodulatory activity. The involvement of histamine in various disorders and the importance of receptors in the clinical features have relevant implications in clinical practice. Anti-H1 antihistamines contrast the histamine dependent effects, mainly concerning nasal symptoms and cutaneous itching and wheal. Antihistamines are among the most prescribed drugs in pediatric care. This review updates the practical use of antihistamines in children and adolescents.
References
2. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M. Histaminergic transmission in the mammalian brain. Physiol Rev. 1991;71:1-5.
3. Tatarkiewicz J, Rzodkiewicz P, Zochowska ˙ M, Staniszewska A, Bujalska-Zadro˙zny M. New antihistamines -perspectives in the treatment of some allergic and inflammatory disorders. Arch Med Sci. 2019;15:537-53, http://dx.doi.org/10.5114/aoms.2017.68534.
4. Church MK. Allergy, histamine and antihistamines. Handb Exp Pharmacol. 2017;241:321-31.
5. Bakker RA, Schoonus S, Smit MJ, Timmerman H, Leurs R. Histamine H1-receptor activation of NF-B: roles for G and Gq/11-subunits in constituitive and agonist-mediated signaling. Mol Pharm. 2001;60:1133-42.
6. Berg KA, Clarke WP. Making sense of pharmacology: inverse agonism and functional selectivity. Int J Neuropsychopharmacol. 2018;21:962-77.
7. Parisi GF, Licari A, Papale M, Manti S, Salpietro C, Marseglia GL, Leonardi S. Antihistamines: ABC for the pediatricians. Pediatr Allergy Immunol. 2020;31 Suppl. 24:34-6.
8. Curran MP, Scott LJ, Perry CM. Cetirizine: a review of its use in allergic disorders. Drugs. 2004;64:523-61.
9. Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994;48:617-37.
10. Motola D, Donati M, Biagi C, Calamelli E, Cipriani F, Melis M, et al. Safety profile of H1-antihistamines in paediatrics: an analysis based on data from VigiBase. Pharmacoepidemiol Drug Saf. 2017;26:1164-71.
11. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128, 1139---50.e4.
12. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Antihistamines as important tools for regulating inflammation. Curr Med Chem -Anti-Inflamm Anti-Allergy Agents. 2005;4:81-9.
13. Ritchie AI, Farne HA, Singanayagam A, Jackson DJ, Mallia P, Johnston SL. Pathogenesis of viral infection in exacerbations of airway disease. Ann Am Thorac Soc. 2015;12 Suppl. 2:S115-23.
14. Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Risk of first-generation H(1)-antihistamines: a GA(2) LEN position paper. Allergy. 2010;65:459-66.
15. Yanai K, Yoshikawa T, Yanai A, Nakamura T, Iida T, Leurs R, et al. The clinical pharmacology of non-sedating antihistamines. Pharmacol Ther. 2017;178:148-56.
16. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108 Suppl.:S147-334.
17. De Bryne P, Christiaens T, Boussery k, Mehuys E, Van Winckel M. Are antihistamines effective in children? A review of the evidence. Arch Dis Child. 2017;102:56-60.
18. Hu Y, Sieck DE, Hsu WH. Why are second-generation H1-antihistamines minimally sedating? Eur J Pharmacol. 2015;765:100-6.
19. Nine JS, Rund CR. Fatality from diphenhydramine monointoxication: a case report and review of the infant, pediatric, and adult literature. Am J Forensic Med Pathol. 2006;27:36-41.
20. Giallongo A, Parisi GF, Licari A, Pulvirenti G, Cuppari C, Salpietro C, et al. Novel therapeutic targets for allergic airway disease in children. Drugs Context. 2019;8:212590.
21. Goindi S, Dhatt B, Kaur A. Ethosomes-based topical delivery system of antihistaminic drug for the treatment of skin allergies. J Microencapsul. 2014;31:716-24.
22. Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc. 1996;17:185-9.
23. Licari A, Ciprandi G, Marseglia A, Castagnoli R, Barberi S, et al. Current recommendations and emerging options for the treatment of allergic rhinitis. Expert Rev Clin Immunol. 2014;10:1337-47.
24. Ciprandi G, Buscaglia S, Catrullo A, Pesce G, Fiorino N, Montagna P. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy. 1997;27:182-91.
25. Ciprandi G, Tosca M, Passalaqua G, Canonica G. Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann Allergy Asthma Immunol. 2001;87:222-6.
26. Ciprandi G, Cosentino C, Milanese M, Mondino C. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy. 2001;56:1068-70.
27. Ciprandi G, Tosca MA, Cosentino C, Riccio AM. Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol. 2003;112:S78-82.
28. Ciprandi G, Pronzato C, Ricca V, Varese P, Giacco GSD. Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy. Clin Exp Allergy. 1995;25:871-8.
29. Bro˙zek JL, Bousquet J, Agache I, Agarwal A, Bachert C, BosnicAnticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines - 2016 revision. J Allergy Clin Immunol. 2017;140:950-8.
30. Ciprandi G, Cirillo I, Vizzaccaro A, Milanese M, Tosca MA. Nasal obstruction in patients with seasonal allergic rhinitis: relationships between allergic inflammation and nasal airflow. Intern Arch Allergy Immunol. 2004;134:34-40.
31. Licari A, Castagnoli R, Bottino C, Marseglia A, Marseglia G, Ciprandi G. Emerging drugs for the treatment of perennial allergic rhinitis. Expert Opin Emerg Drugs. 2016;21:57-67.
32. Church MK, Tiongco-Recto M, Ridolo E, Novák Z. Bilastine: a lifetime companion for the treatment of allergies. Curr Med Res Opin. 2019;13:1-10.
33. Santamaría E, Izquierdo I, Valle M, Vermeulen J, Potter P. Rupatadine oral solution for 2-5-year-old children with allergic rhinitis: a safety, open-label, prospective study. J Asthma Allergy. 2018;4:225-31.
34. Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A, et al. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015;6:CD009566.
35. Ciprandi G, Buscaglia S, Pesce G, Bagnasco M. Ocular challenge and hyperresponsiveness to histamine in patients with allergic conjunctivitis. J Allergy Clin Immunol. 1993;91:1227-30.
36. Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68:1102-16.
37. Ciprandi G. Treatment of nonallergic perennial rhinitis. Allergy. 2004;59:16-23.
38. Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: a randomized clinical trial. Allergy Asthma Proc. 2018;39:110-6, http://dx.doi.org/10.2500/aap.2018.39.4116.
39. Sharma M, Bennett C, Carter B, Cohen SN. H1-antihistamines for chronic spontaneous urticaria: an abridged Cochrane Systematic Review. J Am Acad Dermatol. 2015;73, 710-6.e4.
40. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy. 2018;73:1393-414.
41. Papadopoulos NG, Zuberbier T. The safety and tolerability profile of bilastine for chronic urticaria in children. Clin Transl Allergy. 2019;9:55.
42. Potter P, Mitha E, Barkai L. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. Pediatr Allergy Immunol. 2016;27:55-61.
43. Parisi GF, Papale M, Tardino LG, Manti S, Cuppari C, Salpietro C, Leonardi S. Omalizumab treatment in a 12-year-old girl with chronic spontaneous urticaria. J Dermatol Treat. 2018;29 Suppl. 4:10-1.
44. Metz M, Wahn U, Gieler U, Stock P, Schmitt J, Blume-Peytavi U. Chronic pruritus associated with dermatologic disease in infancy and childhood: update from an interdisciplinary group of dermatologists and pediatricians. Pediatr Allergy Immunol. 2013;24:527-39.
45. Klinnert MD, Booster G, Copeland M, Darr JM, Meltzer LJ, Miller M, et al. Role of behavioral health in management of pediatric atopic dermatitis. Ann Allergy Asthma Immunol. 2018;120:42-8.
46. Yeom M, Ahn S, Oh JY, Kim SY, Lee H, Hahm DH, et al. Atopic dermatitis induces anxiety- and depressive-like behaviors with concomitant neuronal adaptations in brain reward circuits in mice. Neuropsychopharmacol Biol Psychiatry. 2019;98:109818.
47. Hong CH, Joseph M, Kim VH, Lansang P, Lara-Corrales I. Approach to the assessment and management of pediatric patients with atopic dermatitis: a consensus document. Section II: Comorbid disease in pediatric atopic dermatitis. J Cutan Med Surg. 2019;23 Suppl.:12S-8S.
48. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116-32.
49. National Institute for Health and Clinical Excellence. Atopic eczema in children: management of atopic eczema in children from birth up to the age of 12 years; 2007. http://www.nice.org.uk/guidance/CG57
50. Church MK, Maurer M. H1-Antihistamines and itch in atopic dermatitis. Exp Dermatol. 2015;24:332-3.
51. Ciprandi G, Cirillo I. The lower airway pathology of rhinitis. Update review. J Allergy Clin Immunol. 2006;118:1105-9.
52. Ciprandi G, Caimmi D, Miraglia del Giudice M, La Rosa M, Salpietro C, Marseglia GL. Recent developments in united airways disease. Allergy Asthma Immunol Res. 2012;4:171-7.
53. Ciprandi G, Marseglia GL, Klersy C, Tosca MA. Relationships between allergic inflammation and nasal airflow in children with persistent allergic rhinitis due to mite sensitization. Allergy. 2005;60:957-60.
54. Ciprandi G, Cirillo I, Klersy C, Marseglia GL, Vizzaccaro A, Pallestrini E, et al. Role of FEF25-75 as an early marker of bronchial impairment in patients with seasonal allergic rhinitis. Am J Rhinol. 2006;20:641-7.
55. Bachert C, Maspero J. Efficacy of second-generation antihistamines in patients with allergic rhinitis and comorbid asthma.
J Asthma. 2011;48:965-73.
56. Licari A, Manti S, Castagnoli R, Parisi GF, Salpietro C, Leonardi S, Marseglia GL. Targeted therapy for severe asthma in children and adolescents: current and future perspectives. Paediatr Drugs. 2019;21:215-37.
57. Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernández Rivas M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69:1026-45.
58. Muraro A, Mendoza Hernandez DA. Managing food allergy and anaphylaxis: a new model for an integrated approach. Allergol Int. 2019, http://dx.doi.org/10.1016/j.alit.2019.10.004. S1323-8930(19)30168-6.
59. Nurmatov UB, Rhatigan E, Simons FE, Sheikh A. H1- antihistamines for primary mast cell activation syndromes: a systematic review. Allergy. 2015;70(9):1052-61, http://dx.doi.org/10.1111/all.12672, sep; Epub 2015 Jul 6.
60. Juckett G. Arthropod bites. Am Fam Physician. 2013;88:841-7.
61. Tebruegge M, Kuruvilla M, Margarson I. Does the use of calamine or antihistamine provide symptomatic relief from pruritus in children with varicella-zoster infection? Arch Dis Child. 2006;91:1035-6.
62. De Sutter AI, Saraswat A, van Driel ML. Antihistamines for the common cold. Cochrane Database Syst Rev. 2015;11:CD009345.